Business Wire

INCEPTO

19.9.2022 09:01:34 CEST | Business Wire | Press release

Share
Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today. The financing round is led by LBO France's Venture - Digital Health team, with the participation of Wille Finance and the historical investors AXA Venture Partners, the Patient Autonome fund of Bpifrance and Karista. This financing marks a new stage for Incepto, which is launching its offer in four new countries in Europe (Germany, Spain, Italy and Portugal).

As part of Incepto’s development, four new subsidiaries are created in Germany, Spain, Italy and Portugal with the aim of anchoring its position as European leader in the sector and treat one million European patients per month by 2024.

From a French start-up to a European scale-up

Incepto is also announcing the signing of five new partnerships (IB Lab, Milvue, PAIRE, SmartSoft and Thirona) to expand its portfolio of medical imaging applications for emergency care, oncology, orthopaedics, rheumatology and pneumology.

By extending its geographical coverage and developing its portfolio of applications, Incepto is responding to major public health issues: reducing waiting times for examinations, mitigating the lack of specialists for certain serious diseases and supporting doctors' work in the face of the increasing amount of data to be analysed.

In light with the explosion of the AI market in Europe, Incepto has three strategic objectives:

Selecting and make available the most powerful AI solutions in medical imaging for each specialty, guaranteeing high quality standards;

Creating, with doctors new applications that meet real needs but that do not exist yet: ARVA and KEROS are thus the first products co-developed by Incepto for the diagnostic assistance of aortic aneurysms in CT scanners and for MRI of the knee;

Supporting the transformation of organisations and working methods by rethinking patient care with medical teams to exploit the full potential of artificial intelligence technologies.

About Incepto

Created in 2018, Incepto is the first European platform for artificial intelligence solutions applied to medical imaging. With a hundred clinics equipped with their AI solutions and already more than 100,000 patients monitored every month, Incepto's mission is twofold: to help doctors identify the most efficient solutions and put them at their service, while co-creating new applications with them, adapted to their specific needs. Incepto's ambition is to assist doctors on a daily basis in improving the accuracy of diagnoses, the treatment process and the quality of patient care.

https://incepto-medical.com/fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005036/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye